I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025
I-Mab, a U.S.-based global biotech company, announced that their givastomig combination study abstract has been selected for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025.
The study focuses on combining givastomig with nivolumab and chemotherapy for cancer treatment. The congress will take place from July 2-5 in Barcelona, Spain. Chief Medical Officer Dr. Phillip Dennis expressed enthusiasm about the acceptance of their clinical data for presentation.
The company, which specializes in developing precision immuno-oncology agents, will provide additional details about the presentation as more information becomes available from the conference.
I-Mab, un'azienda biotecnologica globale con sede negli Stati Uniti, ha annunciato che l'abstract dello studio sulla combinazione di givastomig è stato selezionato per una presentazione mini-oral al Congress ESMO sui Tumori Gastrointestinali 2025.
Lo studio si concentra sulla combinazione di givastomig con nivolumab e chemioterapia per il trattamento del cancro. Il congresso si svolgerà dal 2 al 5 luglio a Barcellona, Spagna. Il Chief Medical Officer, Dr. Phillip Dennis, ha espresso entusiasmo per l'accettazione dei loro dati clinici per la presentazione.
L'azienda, specializzata nello sviluppo di agenti di immuno-oncologia di precisione, fornirà ulteriori dettagli sulla presentazione non appena saranno disponibili maggiori informazioni dal congresso.
I-Mab, una compañía biotecnológica global con sede en EE.UU., anunció que el resumen del estudio de combinación de givastomig ha sido seleccionado para una presentación mini-oral en el Congreso ESMO de Cánceres Gastrointestinales 2025.
El estudio se centra en la combinación de givastomig con nivolumab y quimioterapia para el tratamiento del cáncer. El congreso se llevará a cabo del 2 al 5 de julio en Barcelona, España. El Director Médico, Dr. Phillip Dennis, expresó entusiasmo por la aceptación de sus datos clínicos para la presentación.
La compañía, especializada en el desarrollo de agentes de inmuno-oncología de precisión, proporcionará más detalles sobre la presentación a medida que haya más información disponible del congreso.
I-Mab는 미국에 본사를 둔 글로벌 바이오텍 기업으로, givastomig 병용 연구 초록이 ESMO 위장관암 학회 2025에서 미니 구두 발표로 선정되었다고 발표했습니다.
이 연구는 암 치료를 위해 givastomig을 nivolumab 및 화학요법과 병용하는 것에 중점을 두고 있습니다. 학회는 7월 2일부터 5일까지 스페인 바르셀로나에서 개최됩니다. 최고 의료 책임자인 필립 데니스 박사는 임상 데이터 발표가 승인된 것에 대해 기대감을 표명했습니다.
정밀 면역종양학 약물 개발을 전문으로 하는 이 회사는 학회에서 추가 정보가 공개되는 대로 발표에 관한 세부 사항을 제공할 예정입니다.
I-Mab, une entreprise biotechnologique mondiale basée aux États-Unis, a annoncé que le résumé de leur étude sur la combinaison de givastomig a été sélectionné pour une présentation mini-oral lors du Congrès ESMO sur les Cancers Gastro-intestinaux 2025.
L'étude porte sur la combinaison de givastomig avec le nivolumab et la chimiothérapie pour le traitement du cancer. Le congrès se tiendra du 2 au 5 juillet à Barcelone, en Espagne. Le directeur médical, Dr Phillip Dennis, a exprimé son enthousiasme quant à l'acceptation de leurs données cliniques pour la présentation.
L'entreprise, spécialisée dans le développement d'agents d'immuno-oncologie de précision, fournira des détails supplémentaires sur la présentation dès que plus d'informations seront disponibles lors du congrès.
I-Mab, ein globales Biotechnologieunternehmen mit Sitz in den USA, gab bekannt, dass ihr Abstract zur Kombinationstherapie mit givastomig für eine Mini-Poster-Präsentation auf dem ESMO Gastrointestinal Cancers Congress 2025 ausgewählt wurde.
Die Studie konzentriert sich auf die Kombination von givastomig mit Nivolumab und Chemotherapie zur Krebsbehandlung. Der Kongress findet vom 2. bis 5. Juli in Barcelona, Spanien, statt. Der Chief Medical Officer, Dr. Phillip Dennis, zeigte sich begeistert über die Annahme ihrer klinischen Daten zur Präsentation.
Das Unternehmen, das sich auf die Entwicklung präziser Immunonkologie-Wirkstoffe spezialisiert hat, wird weitere Details zur Präsentation bekanntgeben, sobald weitere Informationen vom Kongress vorliegen.
- Givastomig study abstract selected for oral presentation at major oncology conference ESMO GI 2025
- Mini-oral presentation format indicates potentially significant clinical findings worth highlighting
- None.
The ESMO Gastrointestinal Cancers Congress to be held July 2-5 in Barcelona
ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for a combination study of givastomig plus nivolumab and chemotherapy has been accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, which will be held July 2-5 in Barcelona, Spain.
“We are very pleased to receive confirmation that new clinical data for givastomig has been accepted as an oral presentation at the upcoming ESMO Gastrointestinal Cancers Congress 2025. As more information becomes available from the conference, we look forward to providing further details about the presentation,” said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab.
About Givastomig
Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (“CLDN18.2”)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line (“1L”) metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential combined effect of proximal interaction between CLDN18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.
The Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment is progressing well in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data.
Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio.
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab Forward Looking Statements
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “believes”, “designed to”, “anticipates”, “future”, “intends”, “plans”, “potential”, “estimates”, “confident”, and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab’s beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s pipeline and clinical development of I-Mab’s drug candidates, including givastomig; the projected advancement of the Company’s portfolio and anticipated milestones and related timing; the Company’s expectations regarding the impact of data from ongoing and future clinical trials the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab’s drug candidates; I-Mab’s ability to achieve commercial success for its drug candidates, if approved; I-Mab’s ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab’s reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab’s limited operating history and I-Mab’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the “Risk Factors” section in I-Mab’s annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab’s subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.
I-Mab Investor & Media Contacts
| PJ Kelleher | |
| LifeSci Advisors | |
| +1-617-430-7579 | |
| pkelleher@lifesciadvisors.com | |
| IR@imabbio.com |
FAQ
What is givastomig being presented at ESMO GI 2025 by I-Mab (IMAB)?
When and where will I-Mab (IMAB) present its givastomig study results?
What type of presentation will I-Mab (IMAB) give for givastomig at ESMO GI 2025?
What is the combination therapy being studied in I-Mab's (IMAB) givastomig presentation?
What is I-Mab's (IMAB) focus in cancer treatment development?
